These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 10712355)
1. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Matsui K; Takeda K; Yu ZX; Valencia J; Travis WD; Moss J; Ferrans VJ Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):1002-9. PubMed ID: 10712355 [TBL] [Abstract][Full Text] [Related]
2. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Logginidou H; Ao X; Russo I; Henske EP Chest; 2000 Jan; 117(1):25-30. PubMed ID: 10631194 [TBL] [Abstract][Full Text] [Related]
3. Expression of human telomerase reverse transcriptase in lymphangioleiomyomatosis. Kumaki F; Takeda K; Yu ZX; Moss J; Ferrans VJ Am J Respir Crit Care Med; 2002 Jul; 166(2):187-91. PubMed ID: 12119231 [TBL] [Abstract][Full Text] [Related]
4. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Matsui K; Takeda K; Yu ZX; Travis WD; Moss J; Ferrans VJ Arch Pathol Lab Med; 2000 Feb; 124(2):267-75. PubMed ID: 10656737 [TBL] [Abstract][Full Text] [Related]
5. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. Gao L; Yue MM; Davis J; Hyjek E; Schuger L Virchows Arch; 2014 Apr; 464(4):495-503. PubMed ID: 24570392 [TBL] [Abstract][Full Text] [Related]
6. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. Ferrans VJ; Yu ZX; Nelson WK; Valencia JC; Tatsuguchi A; Avila NA; Riemenschn W; Matsui K; Travis WD; Moss J J Nippon Med Sch; 2000 Oct; 67(5):311-29. PubMed ID: 11031360 [TBL] [Abstract][Full Text] [Related]
8. Steroid receptor expression in endometria from women treated with tamoxifen. Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688 [TBL] [Abstract][Full Text] [Related]
9. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer. al-Alwan NA; al-Kubaisy W; al-Rawaq K East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of proteins of the Bcl-2 family in pulmonary lymphangioleiomyomatosis: association of Bcl-2 expression with hormone receptor status. Usuki J; Horiba K; Chu SC; Moss J; Ferrans VJ Arch Pathol Lab Med; 1998 Oct; 122(10):895-902. PubMed ID: 9786350 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis. Grzegorek I; Lenze D; Chabowski M; Janczak D; Szolkowska M; Langfort R; Szuba A; Dziegiel P Anticancer Res; 2015 Jun; 35(6):3353-60. PubMed ID: 26026095 [TBL] [Abstract][Full Text] [Related]
12. Tamoxifen lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of ER-positive non-small cell lung cancer cells. Wang XY; Wang Y; Liu HC Biomed Pharmacother; 2011 Oct; 65(7):525-8. PubMed ID: 21993004 [TBL] [Abstract][Full Text] [Related]
14. Matrix proteoglycans and remodelling of interstitial lung tissue in lymphangioleiomyomatosis. Merrilees MJ; Hankin EJ; Black JL; Beaumont B J Pathol; 2004 Jun; 203(2):653-60. PubMed ID: 15141380 [TBL] [Abstract][Full Text] [Related]
15. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. Glassberg MK; Elliot SJ; Fritz J; Catanuto P; Potier M; Donahue R; Stetler-Stevenson W; Karl M J Clin Endocrinol Metab; 2008 May; 93(5):1625-33. PubMed ID: 18285421 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. Colley MH; Geppert E; Franklin WA Am J Surg Pathol; 1989 Sep; 13(9):803-7. PubMed ID: 2764227 [TBL] [Abstract][Full Text] [Related]
17. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma. Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247 [TBL] [Abstract][Full Text] [Related]
19. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Hilsenbeck SG; Osborne CK Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123 [TBL] [Abstract][Full Text] [Related]
20. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]